EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Lp(a) and thromboembolism: current state of knowledge and unsolved issues

Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, Anetta Undas

Archives of Medical Science · 2024-12-13

DOI: 10.5114/aoms/197357 ↗
AbstractBibliografische Angaben

Abstract

Lipoprotein(a) [Lp(a)], a low-density lipoprotein-like particle containing apolipoprotein(a) [apo(a)], is a genetically determined independent risk factor for cardiovascular disease. Elevated Lp(a) levels, present in ~20% of Europeans, are linked to myocardial infarction, ischemic stroke, calcific aortic valve disease, and other cardiac events. Its role in venous thromboembolism (VTE) remains controversial despite shared arterial and venous mechanisms. Elevated Lp(a), particularly smaller apo(a) isoforms, exhibits antifibrinolytic effects by inhibiting plasminogen activation via interactions with plasminogen, tissue-type plasminogen activator, and fibrin. Prothrombotic mechanisms include increased plasminogen activator inhibitor-1 (PAI-1) production, formation of denser fibrin networks, platelet activation, enhanced oxidation of phospholipids, and tissue factor dysregulation. Emerging therapies targeting Lp(a) could reduce thromboembolic risks. This review summarizes Lp(a)'s prothrombotic and antifibrinolytic actions, clinical associations with thromboembolism, and the role of oxidized phospholipids in explaining discrepancies in VTE-related findings.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →